Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (211-220 of 439) with videos related to

Pageof 44
Sort By:
Science Translational Medicine|June 22, 2022
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemiaWilliam Grey, Ana Rio-Machin, Pedro Casado, et al.
Nature Communications|August 5, 2018
Genomic instability in mutant p53 cancer cells upon entotic engulfmentHannah L Mackay, David Moore, Callum Hall, et al.
The Lancet. Oncology|May 13, 2023
Utility of polygenic risk scores in UK cancer screening: a modelling analysisCatherine Huntley, Bethany Torr, Amit Sud, et al.
Nature|September 9, 2021
Using DNA sequencing data to quantify T cell fraction and therapy responseRobert Bentham, Kevin Litchfield, Thomas B K Watkins, et al.
BMC Medical Genomics|October 3, 2015
TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimenAndrea Marion Marquard, Nicolai Juul Birkbak, Cecilia Engel Thomas, et al.
Nature|September 6, 2013
HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesisCarrie A Adelman, Rafal L Lolo, Nicolai J Birkbak, et al.
Cancer Discovery|January 18, 2014
Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolutionSally M Dewhurst, Nicholas McGranahan, Rebecca A Burrell, et al.
The Lancet. Oncology|March 2, 2010
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trialsNicolai Juul, Zoltan Szallasi, Aron C Eklund, et al.
Nature Genetics|February 18, 2025
ImmuneLENS characterizes systemic immune dysregulation in aging and cancerRobert Bentham, Thomas P Jones, James R M Black, et al.
Genome Biology|November 27, 2025
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcomaWilliam Cross, Iben Lyskjær, Christopher Davies, et al.
Pageof 44

Showing results (211-220 of 439) with videos related to

Sort By:
Pageof 44
Science Translational Medicine|June 22, 2022
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemiaWilliam Grey, Ana Rio-Machin, Pedro Casado, et al.
Nature Communications|August 5, 2018
Genomic instability in mutant p53 cancer cells upon entotic engulfmentHannah L Mackay, David Moore, Callum Hall, et al.
The Lancet. Oncology|May 13, 2023
Utility of polygenic risk scores in UK cancer screening: a modelling analysisCatherine Huntley, Bethany Torr, Amit Sud, et al.
Nature|September 9, 2021
Using DNA sequencing data to quantify T cell fraction and therapy responseRobert Bentham, Kevin Litchfield, Thomas B K Watkins, et al.
BMC Medical Genomics|October 3, 2015
TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimenAndrea Marion Marquard, Nicolai Juul Birkbak, Cecilia Engel Thomas, et al.
Nature|September 6, 2013
HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesisCarrie A Adelman, Rafal L Lolo, Nicolai J Birkbak, et al.
Cancer Discovery|January 18, 2014
Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolutionSally M Dewhurst, Nicholas McGranahan, Rebecca A Burrell, et al.
The Lancet. Oncology|March 2, 2010
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trialsNicolai Juul, Zoltan Szallasi, Aron C Eklund, et al.
Nature Genetics|February 18, 2025
ImmuneLENS characterizes systemic immune dysregulation in aging and cancerRobert Bentham, Thomas P Jones, James R M Black, et al.
Genome Biology|November 27, 2025
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcomaWilliam Cross, Iben Lyskjær, Christopher Davies, et al.
Pageof 44